Sugi Predict

Sugi Predict / Compounds / SCHEMBL23218358

SCHEMBL23218358

SCHEMBL23218358

COC(=O)C(C(=O)C(C)(C)C)c1cc(Br)ccc1O[Si](C)(C)C(C)(C)C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DRD2 P14416 1/20 0.36
▸ APLNR P35414 2/20 0.34
▸ SMN1; SMN2 Q16637 3/20 0.33
▸ ALDH1A1 P00352 2/20 0.33
▸ MAPT P10636 2/20 0.33
▸ GFER P55789 1/20 0.33
▸ HSD17B10 Q99714 1/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ CYP2C9 P11712 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ LMNA P02545 3/20 0.33
▸ NPSR1 Q6W5P4 2/20 0.33
▸ POLB P06746 2/20 0.33
▸ RAB9A P51151 2/20 0.33
▸ LPAR1 Q92633 1/20 0.33
▸ PTGDR2 Q9Y5Y4 1/20 0.33
▸ ALPL P05186 3/20 0.32
▸ USP2 O75604 1/20 0.32
▸ ALOX15 P16050 1/20 0.32
▸ KDM4E B2RXH2 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23218824 0.84 KDM4E (0.36) DRD2APLNRSMN1; SMN2ALDH1A1LMNA
SCHEMBL29591689 0.84 KDM4E (0.36) DRD2APLNRSMN1; SMN2ALDH1A1LMNA
SCHEMBL2402387 0.82 APLNR (0.35) DRD2APLNRSMN1; SMN2ALDH1A1MAPT
SCHEMBL23218878 0.79 HPGD (0.40) SMN1; SMN2ALDH1A1MAPTGFERHSD17B10
SCHEMBL5715655 0.70 ELANE (0.43) DRD2ALDH1A1LMNARAB9APTGDR2
SCHEMBL2401781 0.69 DRD2 (0.43) DRD2SMN1; SMN2ALDH1A1MAPTHSD17B10
SCHEMBL25373748 0.69 PTGDR2 (0.54) DRD2SMN1; SMN2ALDH1A1MAPTGFER
SCHEMBL932790 0.68 TSHR (0.40) APLNRSMN1; SMN2ALDH1A1MAPTLMNA
SCHEMBL941194 0.68 DRD2 (0.40) DRD2SMN1; SMN2POLBRAB9AALPL
SCHEMBL4816617 0.68 DRD2 (0.45) DRD2SMN1; SMN2POLBRAB9AALPL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 — — US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 — — US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 — — EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 — — CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 — — WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB DRD2 182/4885APLNR 1264/4885SMN1; SMN2 3739/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB DRD2 445/4885APLNR 1434/4885SMN1; SMN2 3669/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.